HCV genotype 2 as a risk factor for reactivation in patients with B‐cell lymphoma undergoing rituximab combination chemotherapy

Arons, E., Suntum, T., Stetler-Stevenson, M. & Kreitman, R.J. (2009) VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood, 114, 4687–4695. Callet-Bauchu, E., Baseggio, L., Felman, P., Traverse-Glehen, A., Berger, F., Morel, D., Gazzo, S., Poncet, C., Thieblemont, C., Coiffier, B., Magaud, J.P. & Salles, G. (2005) Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases. Leukemia, 19, 1818– 1823. Hockley, S.L., Giannouli, S., Morilla, A., Wotherspoon, A., Morgan, G.J., Matutes, E. & Gonzalez, D. (2010) Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. British Journal of Haematology, 148, 666–669. Matutes, E., Wotherspoon, A. & Catovsky, D. (2003) The variant form of hairy-cell leukaemia. Best Practice & Research. Clinical Haematology, 16, 41–56. Matutes, E., Oscier, D., Montalban, C., Berger, F., Callet-Bauchu, E., Dogan, A., Felman, P., Franco, V., Iannitto, E., Mollejo, M., Papadaki, T., Remstein, E.D., Salar, A., Sole, F., Stamatopoulos, K., Thieblemont, C., Traverse-Glehen, A., Wotherspoon, A., Coiffier, B. & Piris, M.A. (2008) Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia, 22, 487–495. Swerdlow, S.H. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, Lyon. Traverse-Glehen, A., Baseggio, L., Bauchu, E.C., Morel, D., Gazzo, S., Ffrench, M., Verney, A., Rolland, D., Thieblemont, C., Magaud, J.P., Salles, G., Coiffier, B., Berger, F. & Felman, P. (2008) Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood, 111, 2253–2260.